Big Pharma backs CMV vaccine
Swiss pharmaceutical giant Novartis has teamed up with an American biotech company to develop the first commercial vaccine for cytomegalovirus (CMV), which kills or disables tens of thousands of infants every year. Because CMV infection does not usually lead to detectable symptoms in otherwise healthy people, only a handful of researchers have endeavored to develop a CMV vaccine. In fact, the virus is one of the top causes of birth defects; a 1999 National Academy of Sciences report estimated t
Bob Grant
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
View Full Profile.
Learn about our Editorial Policies.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
**__Related stories:__***linkurl:A Long Shot on Cytomegalovirus;http://www.the-scientist.com/article/display/36883/
[December 2006]*linkurl:Cytomegalovirus cell receptor;http://www.the-scientist.com/article/display/21486/
[24 July 2003]
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Meet the Author
Bob Grant
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.View full profile
Share
